Entering text into the input field will update the search result below

Moderna price target lowered at Deutsche Bank citing a potential slowdown

Mar. 07, 2022 8:34 AM ETModerna, Inc. (MRNA)By: Dulan Lokuwithana, SA News Editor3 Comments

Moderna To Request Emergency Authorization For Its Vaccine After Positive Trial Results

Maddie Meyer/Getty Images News

Deutsche Bank analyst Emmanuel Papadakis has trimmed his price target on Moderna (NASDAQ:MRNA), predicting a slowdown in the biotech’s prospects in COVID-19 and flu as well as certain additional efforts.

However, Papadakis maintains the Hold rating

Recommended For You

Comments (3)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

My price target is $80.
@blacksaleem shoot. Mine is $8. They’re bragging about their pipeline! What pipeline? More vaccines and boosters? Lol
jara-mill profile picture
@DadRuss72 - Sounds like you don't know much about mRNA. I'd stick to "GameStop" stocks if I were you.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.